细胞周期蛋白依赖激酶
细胞周期蛋白依赖激酶4
疾病
医学
机制(生物学)
后天抵抗
生物信息学
乳腺癌
抗性(生态学)
帕博西利布
癌症
肿瘤科
癌症研究
生物
内科学
细胞周期
细胞周期蛋白依赖激酶2
转移性乳腺癌
生态学
哲学
认识论
作者
Hannah Wingate,Khandan Keyomarsi
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2023-10-02
卷期号:83 (19): 3165-3167
标识
DOI:10.1158/0008-5472.can-23-2608
摘要
Abstract Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed the treatment landscape of patients with hormone receptor–positive breast cancers. However, despite improvements in clinical outcomes, the approximately 70% of patients with tumors that are not intrinsically resistant to a CDK4/6 inhibitor still ultimately acquire resistance, which leads to a dilemma for clinicians when deciding which treatment to offer patients when they demonstrate disease progression on a CDK4/6 inhibitor. As such, many groups have sought to understand the mechanisms of resistance to CDK4/6 inhibitors, mostly focusing on genetic alterations associated with resistance. Though several recurrent mutations have been described, they are not consistent enough to guide clinical practice or generate novel rational treatment options. Two recent publications have used transcriptomic analysis to unravel distinct mechanisms driving resistance to individual CDK4/6 inhibitors and in doing so have identified biomarkers that could potentially help identify the next course of treatment for patients following disease progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI